Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BAMLANIVIMAB\ETESEVIMAB Cause Fibrin d dimer increased? 8 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Fibrin d dimer increased have been filed in association with BAMLANIVIMAB\ETESEVIMAB. This represents 1.0% of all adverse event reports for BAMLANIVIMAB\ETESEVIMAB.

8
Reports of Fibrin d dimer increased with BAMLANIVIMAB\ETESEVIMAB
1.0%
of all BAMLANIVIMAB\ETESEVIMAB reports
0
Deaths
5
Hospitalizations

How Dangerous Is Fibrin d dimer increased From BAMLANIVIMAB\ETESEVIMAB?

Of the 8 reports, 5 (62.5%) required hospitalization.

Is Fibrin d dimer increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BAMLANIVIMAB\ETESEVIMAB. However, 8 reports have been filed with the FAERS database.

What Other Side Effects Does BAMLANIVIMAB\ETESEVIMAB Cause?

Infusion related reaction (309) Dyspnoea (172) Flushing (130) Chest discomfort (103) Back pain (83) Nausea (79) Incorrect dose administered (75) Transcription medication error (67) Chest pain (66) Dizziness (59)

What Other Drugs Cause Fibrin d dimer increased?

ADALIMUMAB (97) RIVAROXABAN (91) PREDNISONE (69) RITUXIMAB (63) APIXABAN (59) ASPIRIN (54) ACETAMINOPHEN (53) LENALIDOMIDE (53) METHOTREXATE (52) BAMLANIVIMAB (49)

Which BAMLANIVIMAB\ETESEVIMAB Alternatives Have Lower Fibrin d dimer increased Risk?

BAMLANIVIMAB\ETESEVIMAB vs BARACLUDE BAMLANIVIMAB\ETESEVIMAB vs BARICITINIB BAMLANIVIMAB\ETESEVIMAB vs BARIUM BAMLANIVIMAB\ETESEVIMAB vs BARNIDIPINE BAMLANIVIMAB\ETESEVIMAB vs BASILIXIMAB

Related Pages

BAMLANIVIMAB\ETESEVIMAB Full Profile All Fibrin d dimer increased Reports All Drugs Causing Fibrin d dimer increased BAMLANIVIMAB\ETESEVIMAB Demographics